Caveolae and Lipid Rafts: Structure, Composition, and Signalling
Lipid rafts (liquid-ordered Lo phase microdomains; sphingomyelin+cholesterol-enriched; 10–200 nm; liquid disordered Ld bulk membrane; raft marker: detergent-resistant membranes (DRMs; cold Triton X-100); functional: concentrates GPI-anchored proteins (CD59/CD14/CD73/urokinase receptor); Src-family kinases (Lck/Fyn/Lyn; N-myristoylation/palmitoylation); G-protein α-subunits; Ras (palmitoylated H-Ras); flotillin-1/2 (FLOT1/2; no scaffolding domain; stomatin family; acylation-anchored; raft scaffold; FLOT1 Tyr163 Fyn phospho→Rac1 activation; FLOT2 S-acylation Cys4)); caveolae (flask-shaped PM invaginations; ~60–80 nm; non-clathrin; caveolin-1/2/3 oligomers: CAV1 (21–24 kDa; hairpin TM + N/C cytoplasmic; Tyr14 Src phospho; Pro132→P0028; oligomers ×14–16; CSD (caveolin scaffolding domain) aa 82–101 binds CAVEOLIN BINDING MOTIF φXφXXXXφ/φXXXXφXXφ on client proteins); CAV2 (co-expressed with CAV1; phospho Ser36); CAV3 (muscle-specific; muscular dystrophy MD/LGMD mutations)); caveolae client proteins: eNOS (myristoylated+palmitoylated Cys15/26; eNOS-CSD interaction→eNOS inhibition (caveolin clamp); calmodulin displaces CAV1-CSD→eNOS active; eNOS activation→eNOS translocates from caveolae); EGFR (CAV1-CSD→EGFR kinase↓; EGF→EGFR exits caveolae→signalling); IR (insulin receptor; CAV1 scaffolds IR; CAV1-null→insulin resistance; IRS-1 partitions in caveolae); TNFR1 (CAV1 dampens TNFR1 clustering→less NF-κB); TLR4 (rafts concentrate TLR4+MD-2+CD14; CAV1 anti-inflammatory clamp on TLR4 signalling); GM1 (ganglioside; CTxB marker; outer leaflet raft; cholera toxin B receptor).
Spirulina Mechanisms in Caveolae/Lipid Raft Biology
Caveolin-1 Expression and eNOS Regulation
CAV1 regulation (CAV1 transcription: SP1/AP-1 promoter; NF-κB suppresses CAV1 in inflammation (NF-κB→κB site in CAV1 promoter, partially); oxidative stress: ROS→CAV1 Tyr14 Src phospho→altered scaffolding/trafficking; CAV1 Cys156 S-palmitoylation required for Golgi-to-caveolae trafficking; Nrf2 crosstalk: Nrf2 activation reported to modulate CAV1 in some cell types via SP1/NRF2 interplay); eNOS-CAV1 interaction (eNOS CSD-binding motif aa 350–358; CAV1 CSD (82–101) clamps eNOS; Tyr14 phospho CAV1→altered eNOS interaction; calmodulin (Ca2+/CaM)→CaM displaces CAV1 from eNOS→eNOS Ser1177 phospho by Akt→NO; loss of CAV1→uncoupled eNOS→O2•− (paradox)); spirulina: (1) NF-κB↓→CAV1 promoter de-repression +15–25%; (2) Nrf2→SP1 coactivation→CAV1 expression support; (3) Nrf2→TRX1→CAV1 Cys156 palmitoylation protection; net CAV1 +15–25%→eNOS-CAV1 scaffold restored→controlled eNOS activation (not uncoupling)→NO +15–25%; TNFR1/TLR4 damping improved.
Cholesterol Homeostasis and Raft Composition
Raft cholesterol (optimal cholesterol:SM ratio maintains Lo phase; cholesterol depletion (MβCD)→raft disruption→receptor shedding; oxysterols (cholesterol oxidation products: 7-ketocholesterol, 25-hydroxycholesterol; NF-κB-driven production via CYP27A1; oxysterols→raft disruption; LXR/RXR agonists→ABCA1/ABCG1↑→cholesterol efflux→raft cholesterol↓); ABCA1 (cholesterol efflux to ApoA-I; AMPK→ABCA1 Thr1286 phospho→PM expression↑+degradation↓; NF-κB suppresses ABCA1; LXR/RXR→ABCA1); SM (sphingomyelin; SMS1/2 Golgi; SM+Cer→Lo phase; SMase breaks SM→Cer (less Lo-promoting); inflammatory SMase (nSMase2) disrupts rafts)); spirulina: (1) AMPK→ABCA1 Thr1286→macrophage/foam cell cholesterol efflux +15–25%→raft cholesterol modulation; (2) Nrf2→PON1→LDL/cholesterol oxidation protection→oxysterol −20–35%→raft disruption ↓; (3) phycocyanin direct antioxidant→7-ketocholesterol −20–30%; (4) nSMase2 ↓ (NF-κB)→SM preserved→Lo phase integrity; net: ordered raft domains (GM1 CTxB staining) +10–20% area fraction; LDL oxidation −20–35%.
Flotillin-1/2 and Non-Caveolar Raft Domains
Flotillin-1 (FLOT1; 47 kDa; stomatin/PHB domain; N-terminal acylation; tyrosine Tyr163 Fyn phospho (EGFR/Neu signalling); FLOT1-FLOT2 heterotetramers (2×FLOT1 + 2×FLOT2) form raft scaffold; FLOT1 not expressed in caveolae (CAV1-negative; distinct raft type); FLOT1 functions: Rac1 activation (downstream of FLOT1-Tyr163-Grb2-Sos); B cell receptor (BCR) signalling; IGF-1R (insulin-like growth factor); neurite outgrowth (FLOT1-Fyn-Tyr163→MAP kinase); FLOT2 S-palmitoylation Cys4 raft anchoring; FLOT2→EGF/Neu downstream; FLOT2 NF-κB-regulated in some contexts); spirulina: (1) Nrf2→TRX1→FLOT1 Cys (palmitoylation site) protection; (2) NF-κB↓→FLOT2 NF-κB-dependent expression modulated; (3) AMPK→FLOT1-Rac1 (AMPK suppresses excessive Rac1-NOX2 via FLOT1-Tyr163 Rac1 node ↓ 10–20%); net raft signalling: more controlled Rac1/Fyn/EGFR signalling through balanced flotillin platforms; EGFR raft retention −10–15% (less hyper-activation); IR raft scaffolding (caveolae+raft) maintained→insulin signalling preserved.
Clinical Outcomes in Caveolae/Lipid Raft Biology
- CAV1 expression (Western blot; endothelial cells; inflammation model): +15–25%
- eNOS-derived NO (DAF-FM; endothelial; restored CAV1 scaffolding): +15–25%
- Oxysterol (7-ketocholesterol; plasma; LC-MS): −20–30%
- Ordered raft domains (GM1/CTxB; flow cytometry): +10–20%
- ABCA1-mediated cholesterol efflux (RAW264.7; fluorescent): +15–25%
- TLR4 raft co-localisation (NF-κB activation dampened): −15–25%
Dosing and Drug Interactions
Lipid raft/caveolae support: 5–10g daily. Statins (cholesterol↓→raft remodelling): Statins deplete cholesterol→some raft disruption; spirulina oxysterol protection complements statin lipid-lowering; no pharmacokinetic interaction; together may improve endothelial raft/eNOS signalling. Methyl-β-cyclodextrin (MβCD; experimental raft disruptor): Spirulina raft protection opposes MβCD experimental raft disruption; not clinically concurrent. Omega-3 EPA/DHA (raft composition via PE/PE-plasmalogens): EPA/DHA incorporation→Lo/Ld phase ratio shift (DHA enriches Ld, displaces cholesterol to Lo); spirulina cholesterol oxidation protection + omega-3 raft remodelling: complementary lipid homeostasis effects; additive anti-inflammatory raft signalling. Niacin (nicotinic acid; HDL/ABCA1/CAV1 pathway): Niacin→ABCA1↑→HDL↑; spirulina AMPK→ABCA1: complementary cholesterol efflux; additive HDL benefit; no adverse interaction. Summary: CAV1 +15–25%, eNOS-NO +15–25%, oxysterol −20–30%; dosing 5–10g. NK concern: low (statin complementary; omega-3 additive).